Cookies

Like most websites The Pathologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

Screening and monitoring

Diagnostics

The Evolution of Epigenetic Biomarkers

| Niamh Buckley, Laura Feeney, James Beirne, and Paul Mullan

Markers such as DNA methylation, analyzed by liquid biopsy, may improve on ovarian cancer testing options like gold standard CA125

Diagnostics

Sensing the Tiniest Change

| Menno Prins

New biomarker sensing technology can detect miniscule concentrations of molecules in the blood to assist with patient monitoring

Diagnostics

Thinking Outside the (Genome) Box

| Jason Mellad

Epigenetics may combine with liquid biopsy to offer an effective way of detecting early-stage cancers and recurrences

Inside the Lab

Biochip Breakthrough

| Luke Turner

With antimicrobial resistance an ever-increasing threat to modern medicine, a new breakthrough may rapidly identify drug-resistant microbe strains to ensure effective treatment

Outside the Lab

Pre-Empting Relapse

| Luke Turner

A new DNA test that can detect treatment-resistant mutations could prove crucial for patients with acute myeloid leukemia, providing an early indication that targeted therapeutic intervention is needed

Inside the Lab

Gone Fishing

A combination of magnetic particles that bind circulating tumor cells and a magnetic wire that samples them directly from the vein could lead to earlier diagnosis

Subspecialties

An Untrustworthy Myeloma Assay?

The serum free light chain assay for myeloma may miss as many as one in four cases of lambda chain-associated disease, so additional testing is advised

Inside the Lab

Characterizing Cancer

| Luke Turner

Digital spatial profiling technology may enable researchers to identify biomarkers that indicate how patients with high-risk melanoma will respond to treatment

Inside the Lab

A Biomarker for Brain Injury

Measuring the levels of two brain proteins in the blood can yield insight into which TBI patients require CT scanning or surgery

Outside the Lab

Better Biomarkers for AD R&D

| Carlo Medici

For better diagnosis and monitoring of Alzheimer’s disease, as well as drug R&D, we need to move toward widespread use of MRI biomarker imaging, even if blood screening tests become a reality


Register here

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register